Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature

Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) is a universal event and limits clinical efficacy. The third-generation EGFR inhibitor osimertinib is active in EGFR-mutant/T790M positive non-small-cell lung cancer. Mechanisms of acquired resistance are emerging, and here we describe a cis-oriented solvent-front EGFR G796S mutation as the resistance mechanism observed in a progression biopsy and circulating tumor DNA (ctDNA) from a patient with initial response followed by progression on osimertinib. This is one of the earliest reports of a sole solvent-front tertiary EGFR mutation as a resistance mechanism to osimertinib. Our case suggests a monoclonal resistance mechanism. We review the importance of the solvent-front residues across TKIs and describe known osimertinib resistance mechanisms. We observe that nearly all clinical osimertinib-resistant tertiary EGFR mutations are oriented in cis with EGFR T790M. This case highlights the importance of mutations affecting EGFR kinase domains and supports the feasibility of broad panel ctDNA assays for detection of novel acquired resistance and tumor heterogeneity in routine clinical care.

[1]  Yi-long Wu,et al.  Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First‐ and Third‐Generation EGFR TKIs and Shifts Allelic Configuration at Resistance , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  C. Yun,et al.  Structural pharmacological studies on EGFR T790M/C797S. , 2017, Biochemical and biophysical research communications.

[3]  S. Qin,et al.  Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  P. Stephens,et al.  Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. , 2017, Lung cancer.

[5]  Amanda R. Kulick,et al.  SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. , 2017, Cancer research.

[6]  Z. Wang,et al.  EGFR G796D mutation mediates resistance to osimertinib , 2017, Oncotarget.

[7]  R. Corcoran,et al.  Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy , 2017, Genome Medicine.

[8]  J. Shih,et al.  Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[10]  Shuhang Wang,et al.  EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. , 2017, Cancer letters.

[11]  Z. Wang,et al.  Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report , 2017, Oncotarget.

[12]  Young Hak Kim,et al.  Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer , 2016, Molecular Cancer Therapeutics.

[13]  T. Mitsudomi,et al.  Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. , 2016, The Lancet. Oncology.

[14]  Shuhang Wang,et al.  Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors , 2016, Frontiers of Medicine.

[15]  M. Tiseo,et al.  L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  R. Salgia,et al.  Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. , 2016, Cancer letters.

[17]  S. Ou,et al.  High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression. , 2016, Lung cancer.

[18]  Shuhang Wang,et al.  EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer , 2016, Journal of Hematology & Oncology.

[19]  H. Ji,et al.  Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors , 2016, Clinical Cancer Research.

[20]  S. Digumarthy,et al.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis , 2016, Clinical Cancer Research.

[21]  Shuhang Wang,et al.  Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer , 2016, Journal of Hematology & Oncology.

[22]  Haikuo Zhang,et al.  Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors , 2016 .

[23]  M. Ladanyi,et al.  What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC) , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Gang Li,et al.  Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. , 2015, Cancer discovery.

[25]  J. Ahn,et al.  Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  Dong-Wan Kim,et al.  Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  D. Planchard,et al.  EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  L. Sequist,et al.  The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies , 2015, Clinical Cancer Research.

[29]  P. Jänne,et al.  EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors , 2015, Clinical Cancer Research.

[30]  Aleksandra Markovets,et al.  Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.

[31]  J. Byrd,et al.  Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. , 2014, The New England journal of medicine.

[32]  D. Hsiang,et al.  Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  M. Ladanyi,et al.  Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  Kol Jia Yong,et al.  Acquired resistance to crizotinib from a mutation in CD74-ROS1. , 2013, The New England journal of medicine.

[35]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[36]  A. Iafrate,et al.  Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.